SynDevRx Announces Positive Data from Phase 1 Safety Trial of SDX-7320...

SynDevRx has submitted to the FDA results from a Phase 1 dose escalation study in patients with metastatic and progressing solid tumors to assess the safety and tolerability of SDX-7320. Additional...(PRWeb November 16, 2020)Read the full story at https://www.prweb.com/releases/syndevrx_announces_positive_data_from_phase_1_safety_trial_of_sdx_7320_in_late_stage_cancer_patients/prweb17543023.htm
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Source Type: news
More News: Pharmaceuticals | Study